NasdaqGM - Delayed Quote USD

Rani Therapeutics Holdings, Inc. (RANI)

Compare
4.0300 -0.0500 (-1.23%)
At close: June 14 at 4:00 PM EDT
4.0800 +0.05 (+1.24%)
After hours: June 14 at 5:58 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
--
--
--
2,717.0000
462.0000
--
Operating Expense
63,617.0000
66,099.0000
63,451.0000
54,316.0000
17,006.0000
--
Operating Income
-63,617.0000
-66,099.0000
-63,451.0000
-51,599.0000
-16,544.0000
--
Net Non Operating Interest Income Expense
-2,213.0000
-1,784.0000
177.0000
-377.0000
-61.0000
--
Other Income Expense
--
--
--
-1,071.0000
-63.0000
65.0000
Pretax Income
-65,830.0000
-67,883.0000
-63,274.0000
-53,047.0000
-16,668.0000
--
Tax Provision
--
--
70.0000
41.0000
35.0000
--
Net Income Common Stockholders
-33,081.0000
-33,970.0000
-30,588.0000
-8,331.0000
--
--
Diluted NI Available to Com Stockholders
-33,081.0000
-33,970.0000
-30,588.0000
-8,331.0000
--
--
Basic EPS
-1.29
--
-1.28
-0.43
0.00
-1.42
Diluted EPS
-1.29
--
-1.28
-0.43
0.00
-1.42
Basic Average Shares
25,703.5000
--
23,817.0000
19,534.0000
18,738.6820
18,738.6820
Diluted Average Shares
25,703.5000
--
23,817.0000
19,534.0000
18,738.6820
18,738.6820
Total Operating Income as Reported
-63,617.0000
-66,099.0000
-63,451.0000
-51,599.0000
-16,544.0000
--
Total Expenses
63,617.0000
66,099.0000
63,451.0000
54,316.0000
17,006.0000
--
Net Income from Continuing & Discontinued Operation
-33,081.0000
-33,970.0000
-30,588.0000
-8,331.0000
--
--
Normalized Income
-33,081.0000
-33,970.0000
-30,588.0000
-7,549.1700
45.9900
--
Interest Income
2,959.0000
3,301.0000
1,248.0000
89.0000
63.0000
--
Interest Expense
5,172.0000
5,085.0000
1,071.0000
466.0000
124.0000
--
Net Interest Income
-2,213.0000
-1,784.0000
177.0000
-377.0000
-61.0000
--
EBIT
-60,658.0000
-62,798.0000
-62,203.0000
-52,581.0000
-16,544.0000
--
EBITDA
-59,776.0000
-61,976.0000
-61,655.0000
-52,084.0000
-15,955.0000
--
Reconciled Depreciation
882.0000
822.0000
548.0000
497.0000
589.0000
--
Net Income from Continuing Operation Net Minority Interest
-33,081.0000
-33,970.0000
-30,588.0000
-8,331.0000
--
--
Total Unusual Items Excluding Goodwill
--
--
--
-1,071.0000
-63.0000
65.0000
Total Unusual Items
--
--
--
-1,071.0000
-63.0000
65.0000
Normalized EBITDA
-59,776.0000
-61,976.0000
-61,655.0000
-51,013.0000
-15,892.0000
--
Tax Rate for Calcs
--
--
0.0000
0.0003
0.0003
--
Tax Effect of Unusual Items
--
--
--
-289.1700
-17.0100
--
12/31/2019 - 7/30/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TRVI Trevi Therapeutics, Inc.
2.6500
-4.33%
 
VIRX Viracta Therapeutics, Inc.
0.6738
+0.87%
 
VRDN Viridian Therapeutics, Inc.
12.44
-5.40%
 
TNYA Tenaya Therapeutics, Inc.
3.3600
-10.16%
 
ZURA Zura Bio Limited
3.7700
+1.07%
 
VIGL Vigil Neuroscience, Inc.
4.3300
-0.92%
 
SNSE Sensei Biotherapeutics, Inc.
0.6383
-2.99%
 
SABS SAB Biotherapeutics, Inc.
3.1500
-2.48%
 
BNTC Benitec Biopharma Inc.
7.31
-2.14%
 
TELO Telomir Pharmaceuticals, Inc.
5.50
-2.31%